India’s largest drug maker Sun Pharmaceutical announced that it has got USFDA approval for generic copies of Gleevec, a drug that treats chronic myeloid leukemia which is a rare form of blood cancer.
According to the company it has been permitted to launch its version of Gleevec on Feb 01, 2016.
Gleevec’s active ingredient is imatinib mesylate which is patented by Novartis and has annual sales of $2.5 billion in the US.
Sun Pharma said that one of its subsidiaries has received the final approval for 100 mg, and 400 mg tablets.
